Research and Development Collaboration and Option Agreement Sample Contracts
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. October 21, 2024Research and Development Collaboration and Option Agreement • March 6th, 2025 • Molecular Partners Ag • Biological products, (no disgnostic substances)
RE: Research and Development Collaboration and Option Agreement (“Agreement”) dated 5 January 2024 between Orano Med, a French simplified joint-stock company, with registered office at 125 avenue de Paris, 92320 Chatillon, France (“Orano Med”), and Molecular Partners, a Swiss corporation, with registered office at Wagistrasse 14, 8952 Schlieren, Switzerland (“Molecular Partners”) (each, a “Party”, and, collectively, the “Parties”). Unless otherwise noted, capitalized terms used, but not defined herein, shall have the respective meanings ascribed to them in the Agreement, as the context requires.
RESEARCH AND DEVELOPMENT COLLABORATION AND OPTION AGREEMENTResearch and Development Collaboration and Option Agreement • March 14th, 2024 • Molecular Partners Ag • Biological products, (no disgnostic substances)
This Research and Development Collaboration and Option Agreement (this “Agreement”) is made and entered into effective as of 5 January 2024 (the “Effective Date”) by and between Orano Med, a French simplified joint-stock company, with registered office at 125 avenue de Paris, 92320 Chatillon, France (“Orano Med”), and Molecular Partners, a Swiss corporation, with registered office at Wagistrasse 14, 8952 Schlieren, Switzerland (“Molecular Partners”). Molecular Partners and Orano Med may be referred to herein individually as a “Party” or collectively as the “Parties”.